newsfilter
← Latest News
Business Wire·

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026 All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol Additional preliminary data from pivotal cohort